This trial is testing a monoclonal antibody called Avelumab combined with radiation therapy. Researchers are studying whether this combination is safe for treating myeloma and how well it works.
This trial is currently open and accepting patients.
This trial is open label, which means that both you and the researchers running the study will know the doses of Avelumab and radiation you will be receiving.
This study is organized into 28 day cycles, and all patients who join will receive the same regimen.
Patients will receive Avelumab through an intravenous infusion every two weeks (on cycle days 1 and 15). After two doses of Avelumab (one cycle), patients will then receive five radiation therapy treatments on consecutive days. Patients may then continue to receive Avelumab every two weeks indefinitely, as long as they don’t develop bad side effects and their myeloma doesn’t get worse.
Enrollment: 30 patients (estimated)View More
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
View all clinical trial locations sorted by state.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message